Literature DB >> 7532830

Nitric oxide and opioid tolerance.

A M Babey1, Y Kolesnikov, J Cheng, C E Inturrisi, R R Trifilletti, G W Pasternak.   

Abstract

Under conditions in which NG-nitro-L-arginine (NOArg) treatment prevents morphine tolerance, NOArg induces a slow progressive inhibition of nitric oxide synthase (NOS), starting at approx. 20% after a single treatment and increasing to approx. 65% after 10 days. Studies designed to examine potential changes in NOS levels with chronic morphine administration reveal no change. Total NOS activity in both brainstem and cerebellum homogenates is unchanged, as are levels of NOS mRNA in a variety of brain regions. L-Arginine, the precursor of nitric oxide (NO), accelerates tolerance when coadministered with morphine and when given alone L-arginine decreases morphine's potency. Administration of L-arginine alone for 3-10 days shifts morphine's dose-response curve over 2-fold to the right while D-arginine is without effect, as is daily administration of L-arginine along with the NOS inhibitor NOArg. Thus, chronic L-arginine induces "tolerance" in opioid naive mice through NOS. Together, our data indicate an important role for NO in the modulation of opioid analgesia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7532830     DOI: 10.1016/0028-3908(94)90050-7

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

1.  Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance.

Authors:  Y A Kolesnikov; Y X Pan; A M Babey; S Jain; R Wilson; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  NO-ergic neurons of the cervical nucleus of the rat brain in normal conditions and after administration of opiates.

Authors:  I V Dyuizen; I I Deridovich; R A Kurbatskii; V V Shorin
Journal:  Neurosci Behav Physiol       Date:  2004-07

3.  When it comes to opiates, just say NO.

Authors:  Gavril W Pasternak
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

4.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

Review 5.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

6.  Antinociceptive synergistic interaction between morphine and n omega-nitro 1-arginine methyl ester on thermal nociceptive tests in the rats.

Authors:  H Yamaguchi; H Naito
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

7.  Periaqueductal gray neuroplasticity following chronic morphine varies with age: role of oxidative stress.

Authors:  D Bajic; C B Berde; K G Commons
Journal:  Neuroscience       Date:  2012-09-19       Impact factor: 3.590

8.  Morphine-enhanced apoptosis in selective brain regions of neonatal rats.

Authors:  Dusica Bajic; Kathryn G Commons; Sulpicio G Soriano
Journal:  Int J Dev Neurosci       Date:  2013-03-07       Impact factor: 2.457

9.  Role of nitric oxide in the induction and expression of morphine tolerance and dependence in mice.

Authors:  Y M Dambisya; T L Lee
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

10.  The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity.

Authors:  Keith A Trujillo
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.